Current location: slot bet kecil apk > hitam slot bet > 50jili live > main body

50jili live

2025-01-13 2025 European Cup 50jili live News
Stock futures are flat Sunday ahead of shortened trading week: Live updatesBETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") OSUR , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock's first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals. Test results are expected to be provided in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. In addition, Sherlock has been developing a pipeline of other molecular tests, along with several next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies that have the potential to further reduce costs and improve performance of its platforms. Sherlock's CT/NG self-test is in clinical studies and is expected to be submitted to the FDA by the end of 2025 for review. Subject to regulatory approvals, revenue from Sherlock's CT/NG test is expected to contribute to OTI's growth beginning in 2026, benefitting from OraSure's existing infrastructure, commercial capabilities, and strong customer relationships. OTI estimates that testing for CT/NG represents a total addressable market of more than $1.5 billion. The vast majority of CT/NG tests in the U.S. are processed in a centralized lab, and the introduction of an affordable, rapid self-test has the potential to drive significant incremental market expansion. Additionally, public health channels play a key role in STI screening, which is an area where OraSure has a strong presence. "The acquisition of Sherlock represents the next step in OTI's innovation strategy," said Carrie Eglinton Manner, President and CEO of OraSure. "Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock's talented team to OTI and believe that Sherlock's unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond." Conference Call Information OraSure will host a conference call to discuss the acquisition of Sherlock Biosciences at 5:00 p.m. ET on Thursday, Dec. 19, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days. To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email. https://register.vevent.com/register/BIb938f5bae2a442d9acdb83f4bdd9286d About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com Forward Looking Statements This press release contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company's acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company's ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock's ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for the Company's COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company's products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company's products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company's stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving the Company's systems or those of the Company's third-party contractors and IT service providers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures and banking stability. These and other factors that could affect the Company's results are discussed more fully in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the Company's registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and the Company undertakes no duty to update these statements. Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications investorinfo@orasure.com media@orasure.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.50jili live

Victorian family farms list for more than $24 million-combinedIf you've been following the currents of online culture over the past couple of weeks, there's a good chance you've heard about Bluesky with increasing frequency. The microblogging site, which was founded by a former Twitter CEO, has been skyrocketing in popularity since the presidential election earlier this month, in which Donald Trump won his second term in the White House. Some users of X (formerly known as Twitter), many of whom were already growing frustrated with the many changes made by its owner, Trump mega-donor Elon Musk, are finally jumping ship to Bluesky. Aside from being less politically fraught, Bluesky is fundamentally different from X/Twitter in a few key ways. Its decentralized structure means users have more freedom with their data, and it has several features that make it easier to find the kind of content you're looking for — or avoid the content you're not. But can this brash new upstart really unseat X as the de-facto microblogging site? To find out, we took Bluesky through its paces and spoke to experts. Bluesky was founded by former Twitter CEO Jack Dorsey , along with a number of people interested in decentralized technology — tech designed so that it isn't subject to the whims of a single company or its owner. The idea was that anyone could host their own instance of Bluesky, leaving the company responsible only for its own app and not for the platform as a whole. It may seem strange for the head of a company to work on a potential competitor, but Dorsey has a reputation as an iconoclast within Silicon Valley. In fact, further Twitter alumni got in on the ground floor of Bluesky, including Parag Agrawal, the CEO whose tenure stretched from Dorsey's exit to Elon Musk's arrival at the company. But when it came time to launch as its own company, Dorsey and Agrawal tapped Lantian "Jay" Graber, a promising young developer, as Bluesky's CEO. The decision to keep Bluesky independent of Twitter proved prophetic. When Elon Musk took over the latter company in late 2022, he promptly nullified a prior agreement that would have seen Twitter folded into the decentralized web of platforms using Bluesky's technology and fired the people working to incorporate that tech. However, as Twitter changed under its new owner and was eventually rebranded as X, Bluesky continued to develop in the background. After a beta period during which sign-ups were available via invite only, Bluesky opened its doors to the general public in early 2024. Since then, it has grown slowly, but the platform began to explode in mid-November 2024. On the surface, Bluesky may look like just another Twitter clone, but under the hood, it's a very different platform. Just as on Twitter, you can post, repost, quote, and like posts. The difference is that Bluesky is decentralized, meaning anyone can host their own data and take their account with them to another instance of the platform. By default, a new user will appear as @username.bsky.social, but if you don't like that, you can use your own domain. For example, SlashGear could theoretically rehost an account on its own domain, giving it a username like @username.slashgear.com. (At the time of this writing, SlashGear does not have a Bluesky account.) Another unique aspect of Bluesky is algorithmic choice. On Twitter, Threads, and many other social media sites, users are shown content based on a secretive algorithm closely guarded by the platform. On Twitter and Threads, you can choose between letting a proprietary algorithm decide what you see or sorting your timeline into pure chronological order. Bluesky, by contrast, lets you select between multiple open-source algorithms, giving users far more control over how their content gets sorted. This algorithmic control manifests most clearly in the Feeds feature, which lets users create and subscribe to custom timelines based on particular topics, sets of users, or other criteria. When creating a Feed, you can choose which algorithm you want to rank the posts and even select how much weight the algorithm will give to the recency of any given post. This feature helped Bluesky to take on a life of its own, with a community-curated DIY culture that feels both fresh and distinct from other Twitter-like competitors. Buzz around Bluesky spread quickly through tech and media circles at its initial launch, hitting a million app installs last year . Now, it's taken on new life since the 2024 presidential election. With X owner Elon Musk having thrown his weight behind President-elect Donald Trump, many X users who don't align with Musk's politics now see the platform as politically hostile. That feeling was egged on by the explosion of hate speech that coincided with Musk's loosened moderation on the site, some of which Musk himself has engaged with. SlashGear reached out to journalist and Internet culture expert Taylor Lorenz, who says of X, "It's a very intense political environment on the app, and Elon has removed user controls that used to protect people." The result has been a mass exodus of users, which has been Bluesky's gain. At the time of this writing, Bluesky is the number one app on both the Apple App Store and Google Play Store, where it has remained for several days. Bluesky is not the only alternative to X. Meta's Threads platform integrates seamlessly with Instagram and has already scored 175 million users as of July 2024. However, given that the point of leaving X was to escape from under the thumb of a tech billionaire, it's understandable that Threads, which is ultimately tied to Meta CEO Mark Zuckerberg, would prove nearly as unpalatable for a large portion of expatriated X users. "Threads ended up going crazy with the content moderation," Lorenz said, "and now I think people are realizing that Bluesky is the best alternative. Bluesky offers a very comparable experience to kind of the original Twitter." While Bluesky is benefitting from the X exodus, whether the current spike in growth can continue as a long-term trend remains to be seen. Lorenz suggested that, due to Elon Musk's entrenchment in the incoming Trump administration, X will remain an important part of the media landscape. "I think political people are so incredibly addicted to Twitter," Lorenz says. "And now with Trump in office, Twitter is going to remain a politically relevant platform that keeps journalists on there because they're going to want to see what Elon says." Lorenz points out that X also remains the de-facto platform for Congresspeople and other public figures. However, she's not willing to write Bluesky off in that regard just yet. "If lawmakers and pundits and journalists all do go to Bluesky, then I think it could replicate what Twitter had," Lorenz says. Some public figures have already decamped to Bluesky from X, including journalists like New York Times columnist Jamelle Bouie and celebrities like "Star Wars" star Mark Hamill. According to award-winning author Charlie Jane Anders, who referred SlashGear to a public statement on the subject, her final straw was a reported proliferation of child sexual abuse material (CSAM) on X. "I feel the need to make a clean break from Twitter at this point," she wrote. "After all of the proliferation of hate speech, and the random shutdowns of progressive accounts that challenge the owner's rigid orthodoxy, I was already wanting to make a break for it. But after the latest scandals involving CSAM, I really feel as though I have no choice." Whether or not Bluesky becomes the new Twitter, it's clearly promising what many people crave: a fresh start.ASCSN calls for promotion of education officers, civil servants in MDAs



Hundreds gather at Miller Field to see President Biden, first lady’s visit on Staten IslandThe primary market is ending the calendar year 2024 with a bang, buoyed by a slew of companies launching their IPOs before the new year. Earlier today, three IPOs of Vishal Mega Mart , Mobikwik and Sai Life Sciences opened for subscription, leaving investors spoilt for choices. However, Vishal Mega Mart emerged as the clear favourite among all the three IPOs, given that the company has priced the issue attractively (at P/E of 77.2x, lower than retail peers) and it is strategically positioned to benefit from India’s expanding retail market, particularly in tier-2 and tier-3 cities where organized retail penetration remains low. At a PE of 77.2x its earnings, the company currently boasts a market capitalization of Rs 35,168.01 crore. However, one drawback is the complete OFS structure, where the promoter will offload around 102 crore shares. "The company’s focus on cost-efficiency, consumer-centricity, and aggressive expansion in underserved markets strengthens its growth prospects. Additionally, Vishal Mega Mart boasts a strong customer loyalty program that enhances repeat business and engagement. Vishal Mega Mart is the top pick among the IPOs as it offers a compelling investment opportunity with a proven business model and significant room for growth," said Akriti Mehrotra, Research Analyst, StoxBox. "Vishal Mega Mart's financial performance is also steady, with both revenue and profitability increasing in the last few quarters. For high-risk investors looking to gain exposure to the retail industry, this IPO is a good option," said Shivani Nyati, Head of Wealth at Swastika Invest. Stock Trading Options Trading Made Easy: Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Derivative Analytics Made Easy By - Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets View Program Stock Trading Options Scalping Made Easy By - Sivakumar Jayachandran, Ace Scalper View Program Stock Trading Technical Analysis Demystified: A Complete Guide to Trading By - Kunal Patel, Options Trader, Instructor View Program Stock Trading RSI Trading Techniques: Mastering the RSI Indicator By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Market 101: An Insight into Trendlines and Momentum By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Macroeconomics Made Easy: Online Certification Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Dow Theory Made Easy By - Vishal Mehta, Independent Systematic Trader View Program Stock Trading Stock Markets Made Easy By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Advanced Strategies in Stock Market Mastery By - CA Raj K Agrawal, Chartered Accountant View Program Stock Trading Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading A2Z of Stock Market for Beginners: Stock Market Course For Beginners By - elearnmarkets, Financial Education by StockEdge View Program Also Read: Will they make a comeback in 2025? 5 mid-cap stocks from different sectors with an upside potential of up to 30% Meanwhile, if for any reason investors can't pick Vishal Mart's IPO, analysts preferred Mobikwik as the second option. The company is planning to raise Rs 572 crore through the issue and use the proceeds for growth in financial and payment services, research and development in AI and machine learning, and expansion of payment device infrastructure. At its core, Mobikwik Systems is a platform company with a two-way payments network that includes both customers and merchants. The IPO is priced at 113.2x PE. "Investors can apply for both short-term and long-term listing advantages because Vishal Mega Mart and Mobikwik Systems Limited appear to have sound financial figures and fair valuations," said Nyati. Sai Life Sciences is the least preferred among analysts as the CDMO (contract research, development, and manufacturing) company priced the issue at high valuations and the offer includes a significant chunk of OFS. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel )

Garry scores 20, South Dakota State takes down Duquesne 71-60 at Cayman Islands ClassicDonald Trump ’s nominee to oversee the federal government’s enforcement of civil rights has spent the last year leading a legal crusade against transgender Americans, signaling where Trump could start with his “day one” pledge to roll back discrimination protections. Harmeet Dhillon, founder of the Center for American Liberty, has filed a barrage of attention-grabbing lawsuits on behalf of right-wing activists against gender-affirming healthcare and school policies and state and local laws designed to protect LGBT + people across the country . Dhillon also supported efforts to reverse election results in states Trump lost in 2020, and she steered the Trump campaign’s 2024 “election integrity” team in Arizona, a hotbed for bogus election conspiracy theories in the wake of Trump’s loss. Dhillon and attorneys at her firm have been involved in at least 16 lawsuits across seven states and Washington, D.C. to defend Trump and challenge voting rights laws and election rules. Dhillon — whose firm has received more than $8 million in legal fees from Trump’s team — is yet another attorney who has represented the former president or joined in his legal battles before receiving his nomination for a top post at the Department of Justice . If she’s confirmed to lead the civil rights division , she will be in a uniquely powerful position to reshape, and reverse, critical protections for LGBT+ Americans while keeping Trump’s election denialist movement alive at the top of the Justice Department . Trump also shares Dhillon with far-right billionaire Elon Musk, who hired her firm Dhillon Law Group for X’s lawsuit against a group of advertisers who are boycotting his platform. “Harmeet is one of the top Election lawyers in the Country, fighting to ensure that all, and ONLY, legal votes are counted,” Trump said in a statement announcing Dhillon’s nomination on December 9. “In her new role at the DOJ, Harmeet will be a tireless defender of our Constitutional Rights, and will enforce our Civil Rights and Election Laws FAIRLY and FIRMLY.” Dhillon’s Center for American Liberty has filed several medical malpractice lawsuits on behalf of so-called “detransitioners” who now argue against access to gender-affirming healthcare for trans minors by speaking publicly about their regret. The group also threatened legal action and sued several schools over policies that could be used to forcibly out LGBT+ students — policies that Dhillon argues are causing “irreparable harm to children” by violating parents’ rights. One lawsuit against the Los Angeles Unified School District accuses schools of “hiding classroom curriculum on transgenderism and critical race theory.” The group also sued teachers and schools in Maine on behalf of a right-wing activist who opposed school policies that allow trans students to use bathrooms and locker rooms consistent with their gender identity. The Center for American Liberty also sued the YMCA on behalf of an 82-year-old woman who claimed she saw a “grown man” wearing a “women’s bathing suit” and talking to two young girls in a changing room. That “grown man” was a transgender YMCA employee escorting the girls to the bathroom. Julie Jaman asked her if she “had a penis” and was then asked to leave. The Olympic Peninsula YMCA later told Jaman that she was banned for life due to a “pattern of code of conduct violations.” State laws that protect transgender care and abortion providers and patients from out-of-state prosecution are “horrifying” and “super extreme” measures that will turn states into a “refuge for child mutilation,” according to Dhillon and her Center for American Liberty. More than a dozen states have enacted so-called “shield” laws, but anti-trans and anti-abortion activists are demanding federal government pre-emption that would outlaw affirming care and abortion access despite state and local projections. The Biden administration’s expanded anti-discrimination protections for LGBT+ students under Title IX — which prohibits sex-based discrimination in schools — are a “slap in the face to women and girls,” according to Dhillon. “Congress intended Title IX to protect women, not feelings or caricatures of women,” she said. ”But the Biden administration just robbed women of equal opportunities — taking from women and giving to men.” On November 5, 2020, as votes were still being tallied in several states, Dhillon appeared on Fox Business to baselessly suggest election workers in Biden-Harris masks were manipulating ballots in Philadelphia. “We’re waiting for the United States Supreme Court , [in] which the president has nominated three justices, to step in and do something,” she said . “Hopefully, Amy Coney Barrett will come through and pick it up. There’s no guarantee ... so we have to fight this on the ground and make sure that we challenge every place and we are.” She later joined Trump’s legal team to defend him against legal challenges to his ballot eligibility in Colorado, a case that did make its way to the Supreme Court. A group of Colorado voters argued that Trump is ineligible for the presidency under the scope of the 14th Amendment, which bars anyone who has sworn an oath to uphold the Constitution and “engaged in insurrection or rebellion” from holding public office. Similar challenges were filed in a dozen states. The Supreme Court ultimately reversed a Colorado court decision that found Trump unconstitutionally eligible for the president because of his role surrounding the Capitol attack on January 6, what Dhillon called “dangerous overreach that, if left unchallenged, could have set a perilous precedent for future election.” During midterm elections in 2022, election-denying conspiracy theorists Kari Lake and Abraham Hamadeh hired Dhillon’s firm to contest election results in Arizona, where Lake and Hamadeh lost their campaigns for governor and attorney general, respectively. Dhillon was later named to run the Trump campaign’s “election integrity team” in that state.WASHINGTON (AP) — President-elect Donald Trump’s allies on Capitol Hill rallied around Pete Hegseth , Trump’s Pentagon pick, on Thursday even as new details surfaced about allegations that he had sexually assaulted a woman in 2017. The GOP embrace of Hegseth came as another controversial Trump nominee, Matt Gaetz, withdrew from consideration for attorney general. Gaetz said it was clear he had become a “distraction" amid pressure on the House to release an ethics report about allegations of his own sexual misconduct. An attorney for two women has said that his clients told House Ethics Committee investigators that Gaetz paid them for sex on multiple occasions beginning in 2017, when Gaetz was a Florida congressman. Fresh questions over the two nominees' pasts, and their treatment of women, arose with Republicans under pressure from Trump and his allies to quickly confirm his Cabinet. At the same time, his transition has so far balked at the vetting and background checks that have traditionally been required. While few Republican senators have publicly criticized any of Trump's nominees, it became clear after Gaetz's withdrawal that many had been harboring private concerns about him. Oklahoma Sen. Markwayne Mullin, who served with Gaetz in the House, said it was a “positive move.” Mississippi Sen. Roger Wicker said it was a “positive development.” Maine Sen. Susan Collins said Gaetz “put country first and I am pleased with his decision.” After meeting with Hegseth, though, Republicans rallied around him. “I think he’s going to be in pretty good shape,” said Wicker, who is expected to chair the Senate Armed Services Committee in the next Congress. Republican senators' careful words, and their early reluctance to publicly question Trump's picks, illustrated not only their fear of retribution from the incoming president but also some of their hopes that the confirmation process can proceed normally, with proper vetting and background checks that could potentially disqualify problematic nominees earlier. Gaetz withdrew after meeting with senators on Wednesday. Sen. Thom Tillis said Gaetz was “in a pressure cooker” when he decided to withdraw, but suggested that it would have little bearing on Trump’s other nominees. “Transactions — one at a time,” he said. As the Hegseth nomination proceeds, Republicans also appear to be betting that they won't face much backlash for publicly setting aside the allegations of sexual misconduct — especially after Trump won election after being found liable for sexual abuse last year. Hegseth held a round of private meetings alongside incoming Vice President JD Vance on Thursday in an attempt to shore up support and told reporters afterward: “The matter was fully investigated and I was completely cleared, and that’s where I’m gonna leave it.” A 22-page police report report made public late Wednesday offered the first detailed account of the allegations against him. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave. The report cited police interviews with the alleged victim, a nurse who treated her, a hotel staffer, another woman at the event and Hegseth. Listen now and subscribe: Apple Podcasts | Spotify | RSS Feed | SoundStack | All Of Our Podcasts Hegseth’s lawyer, Timothy Palatore, said the incident was “fully investigated and police found the allegations to be false.” Hegseth paid the woman in 2023 as part of a confidential settlement to head off the threat of what he described as a baseless lawsuit, Palatore has said. Wicker played down the allegations against Hegseth, a former Fox News host, saying that “since no charges were brought from the authorities, we only have press reports.” Sen. Bill Hagerty, R-Tenn., said after his meeting with Hegseth that he "shared with him the fact that I was saddened by the attacks that are coming his way.” Hagerty dismissed the allegations as “a he-said, she-said thing” and called it a “shame” that they were being raised at all. The senator said attention should instead be focused on the Defense Department that Hegseth would head. It's one of the most complex parts of the federal government with more than 3 million employees, including military service members and civilians. Sexual assault has been a persistent problem in the military, though Pentagon officials have been cautiously optimistic they are seeing a decline in reported sexual assaults among active-duty service members and the military academies. Wyoming Sen. John Barrasso, who will be the No. 2 Republican in the Senate next year, said after his meeting with Hegseth that the nominee is a strong candidate who “pledged that the Pentagon will focus on strength and hard power – not the current administration’s woke political agenda.” Senate Republicans are under pressure to hold hearings once they take office in January and confirm nominees as soon as Trump is inaugurated, despite questions about whether Trump’s choices will be properly screened or if some, like Hegseth, have enough experience for the job. Senate Armed Services Chairman Jack Reed, who will be the top Democrat on the panel next year, said the reports on Hegseth “emphasized the need for a thorough investigation by the FBI on the background of all the nominees.” It takes a simple majority to approve Cabinet nominations, meaning that if Democrats all opposed a nominee, four Republican senators would also have to defect for any Trump choice to be defeated. Trump has made clear he’s willing to put maximum pressure on Senate Republicans to give him the nominees he wants – even suggesting at one point that they allow him to just appoint his nominees with no Senate votes. But senators insist, for now, that they are not giving up their constitutional power to have a say. “The president has the right to make the nominations that he sees fit, but the Senate also has a responsibility for advice and consent,” said Republican Sen. Mike Rounds of South Dakota. In the case of Gaetz, he said, “I think there was advice offered rather than consent.”

European Cup News

European Cup video analysis

  • 5 traditional filipino games
  • lucky me chicken noodles
  • bmy88. com
  • fb 777 slots
  • live bet
  • bmy88. com